JP Morgan Chase
CYTK icon

JP Morgan Chase’s Cytokinetics CYTK Stock Holding History

JP Morgan Chase’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Buy
+35,000
New +$2.51M ﹤0.01% 3871
2026
Q1 		– Sell
-3,900
Closed -$248K – 7599
2025
Q4 		$248K Buy
3,900
+2,000
+105% +$124K ﹤0.01% 5427
2025
Q3 		$104K Buy
+1,900
New +$78.3K ﹤0.01% 5878
2025
Q1 		– Sell
-6,000
Closed -$282K – 7378
2024
Q4 		$282K Sell
6,000
-30,000
-83% -$1.56M ﹤0.01% 5327
2024
Q3 		$1.9M Buy
36,000
+35,000
+3,500% +$1.95M ﹤0.01% 4044
2024
Q2 		$54.2K Sell
1,000
-35,000
-97% -$2.11M ﹤0.01% 5822
2024
Q1 		$2.52M Buy
36,000
+23,500
+188% +$1.82M ﹤0.01% 3661
2023
Q4 		$1.04M Buy
+12,500
New +$453K ﹤0.01% 4305

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's CYTK Position: Q2 2026 in Review

JP Morgan Chase increased its Cytokinetics (CYTK) stake by 76% in Q2 2026, buying an estimated $49.2M and bringing the position to 1,588,895 shares worth $139M. The position accounts for 0.01% of the portfolio, ranked #910.

JP Morgan Chase first reported a position in CYTK in Q3 2013 and has held it in 39 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • JP Morgan Chase held 1,588,895 shares of Cytokinetics worth $139M as of Q2 2026.
  • JP Morgan Chase bought 685,090 Cytokinetics shares in Q2 2026, an estimated $49.2M.
  • Cytokinetics made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #910 holding.
  • JP Morgan Chase first reported a position in Cytokinetics in Q3 2013 and has held it in 39 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.